Pfizer Files With The FDA For Review Of Axitinib

Pfizer (PFE) announced today that the U.S. Food and Drug Administration has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma. This submission was based on Phase 3 data from the AXIS 1032 trial, comparing axitinib with sorafenib in patients with previously treated advanced RCC, which Pfizer recently presented at the 47th Annual Meeting of the American Society of Clinical Oncology.